Capricor Therapeutics

Historical price data

Capricor Therapeutics is dedicated to developing novel cell and exosome-based therapies for serious rare diseases, with a primary focus on Duchenne muscular dystrophy (DMD). The company's lead asset, Deramiocel, is an allogeneic cardiac-derived cell therapy that has demonstrated significant functional benefits in late-stage clinical trials and is under regulatory review. Capricor's strategy leverages its two synergistic technology platforms—allogeneic cardiosphere-derived cells (CDCs) and the StealthX™ exosome platform—to build a diversified pipeline targeting high-unmet-need conditions.

Capricor's technology is built on two pillars: allogeneic cardiosphere-derived cells (CDCs) for immunomodulation and tissue repair, and the StealthX™ platform for engineering exosomes as targeted delivery vehicles for therapeutic payloads.

In DMD, Deramiocel competes with mutation-specific genetic therapies but is differentiated by its allogeneic, pathology-targeting mechanism applicable to all patients. In exosome technology, it competes with several biotechs on platform capabilities in drug delivery and vaccinology.